Armstrong, April W.
Alexis, Andrew F.
Blauvelt, Andrew
Silverberg, Jonathan I.
Feeney, Claire
Levenberg, Mark
Chan, Gary
Zhang, Fan
Fostvedt, Luke
Clinical trials referenced in this document:
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Documents that mention this clinical trial
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
https://doi.org/10.1007/s40257-022-00738-4
Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
https://doi.org/10.1007/s13555-022-00694-1
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Documents that mention this clinical trial
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Documents that mention this clinical trial
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Documents that mention this clinical trial
Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
https://doi.org/10.1007/s13555-022-00764-4
Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
https://doi.org/10.1007/s40262-021-01104-z
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Documents that mention this clinical trial
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
https://doi.org/10.1007/s40257-021-00618-3
Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01183-3
Funding for this research was provided by:
Pfizer
Article History
Received: 15 February 2024
Accepted: 8 May 2024
First Online: 19 June 2024
Declarations
:
: April W. Armstrong has served as a research investigator and/or scientific advisor for Pfizer Inc., AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, EPI Health, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatologics, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma, and UCB. Andrew F. Alexis has received grants made to the institution from AbbVie, Almirall, Amgen, Arcutis, Bristol Myers Squibb, Cara Therapeutics, Castle, Dermavant, Galderma, LEO Pharma, Novartis, Valeant (Bausch Health), and Vyne; is an advisory board member or consultant for Pfizer Inc., AbbVie, Allergan, Almirall, Alphyn Biologics, Amgen, Apogee Pharmaceuticals, Arcutis, Bausch Health, Beiersdorf, Bristol Myers Squibb, Canfield, Cara Therapeutics, Castle, Cutera, Dermavant, Eli Lilly and Company, EPI Health, Galderma, Incyte, Janssen, LEO Pharma, L’Oréal, Ortho Pharmaceutical, Regeneron Pharmaceuticals, Sanofi Genzyme, Swiss American, VisualDx, Vyne, and UCB; has served as a speaker for Pfizer Inc., Bristol Myers Squibb, Regeneron Pharmaceuticals, and Sanofi Genzyme; and has received royalties from Springer, Wiley-Blackwell, and Wolters Kluwer Health. Andrew Blauvelt has served as a speaker (received honoraria) for Pfizer Inc., AbbVie, Eli Lilly and Company, and UCB; served as a scientific advisor (received honoraria) for Pfizer Inc., AbbVie, Abcentra, Aclaris Therapeutics, Affibody Medical, ALIGOS Therapeutics, Almirall, Alumis Inc., Amgen, AnaptysBio, Apogee Pharmaceuticals, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient Pharmaceuticals, Evelo Biosciences, Evommune Inc., Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Lipidio, Microbion Biosciences, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Q32 Bio Inc., Rani, Rapt, Regeneron Pharmaceuticals, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB, Union, Ventyx, Vibliome, and Xencor; and has acted as a clinical study investigator (the institution has received clinical study funds) for Pfizer Inc., AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo Biosciences, Evommune Inc., Galderma, Incyte, Janssen, LEO Pharma, Merck, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Sun Pharma, UCB, and Ventyx. Jonathan I. Silverberg served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. Fan Zhang was a former employee and shareholder of Pfizer Inc. and is currently an employee of Google LLC. Claire Feeney, Mark Levenberg, Gary Chan, and Luke Fostvedt are employees and shareholders of Pfizer Inc.
: All study documents and procedures were approved by the appropriate institutional review boards/ethics committees at each study site. The studies were conducted in compliance with the ethical principles from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice Guidelines. All local regulatory requirements were followed. Informed consent was obtained from all individual participants included in the study.